Selenium is an essential trace element in mammals, but is toxic at high levels. It is best known for its cancer prevention activity, but cancer cells are more sensitive to selenite toxicity than normal cells. Since selenite treatment leads to oxidative stress, and the Trx (thioredoxin) system is a major antioxidative system, we examined the interplay between TR1 (Trx reductase 1) and Trx1 deficiencies and selenite toxicity in DT cells, a malignant mouse cell line, and the corresponding parental NIH 3T3 cells. TR1-deficient cells were far more sensitive to selenite toxicity than Trx1-deficient or control cells. In contrast, this effect was not seen in cells treated with hydrogen peroxide, suggesting that the increased sensitivity of TR1 deficiency to selenite was not due to oxidative stress caused by this compound.
INTRODUCTION
Selenium plays an important role in decreasing the incidence of cancer and other human diseases [1] [2] [3] [4] . More recently, epidemiological and genetic studies, as well as various molecular approaches and mouse models, have implicated seleniumcontaining proteins (selenoproteins) in having roles in cancer prevention, including colon cancer [5, 6] , prostate cancer [2, 7] and other cancer forms [8] [9] [10] . It should also be noted that smallmolecular-mass selenocompounds, as well as selenoproteins, have been shown to play roles in cancer and other disease prevention, and in-depth reviews have been written on this subject [11] [12] [13] . The fact that both these classes of seleniumcontaining components have anticarcinogenic properties has led to considerable debate in the selenium field regarding which forms of selenium (i.e. small-molecular-mass selenocompounds or selenoproteins) provide greater health benefits. In more recent years, selenoproteins have received by far more attention [14] .
One selenoprotein that appears to participate in cancer prevention is TR1 [Trx (thioredoxin) reductase 1] [15, 16] . TR1 is required for activation of the p53 tumour suppressor and for supporting other tumour suppressor activities [17] , and is targeted by carcinogenic electrophilic compounds [18] . In addition, this selenoenzyme is one of the major redox regulators in mammalian cells and is expressed in all cell types, organs and tissues [15, 19, 20] . The targeted removal of TR1 in mice is embryonic lethal, and this protein also has roles in transcription, cell proliferation and DNA repair [21, 22] . The major function of TR1 in normal cells is to keep Trx in the reduced state; Trx then donates reducing equivalents to numerous cellular proteins, such as peroxiredoxins and methionine sulfoxide reductases [23] . In this manner, one of the major cellular redox systems, the Trx system, is regulated by TR1. The catalytic activity of TR1 that accounts for its function is governed by the Sec (selenocysteine) moiety, which is the C-terminal penultimate amino acid [24] . The above functions of TR1 provide strong evidence that this protein plays a highly significant role in maintaining cellular redox homoeostasis and thus keeping cells in a healthy state. In addition, TR1 deficiency was reported to induce the cytoprotective transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2), which is well known to control gene expression involved with phase II detoxification and antioxidant enzymes against oxidative stress or chemical challenge [25, 26] , but the role of Trx in the regulation of Nrf2 is not completely understood.
TR1 can be considered as having a split personality in that it has roles in preventing cancer and also in promoting and/or sustaining cancer [10] . Indeed, TR1 is overexpressed in many tumours and cancer cells [19] . This enzyme has been designated as a target for cancer therapy, since a variety of potent inhibitors of this selenoenzyme inhibited cancer progression [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . Moreover, certain anticancer drugs targeting TR1 decreased its activity in malignant cells, and consequently, changed the cancer properties of such cells (see [27] [28] [29] and references therein). In addition, TR1 has been shown to be uniquely overexpressed, as compared with other mammalian selenoproteins, in a variety of cancer cell lines [19] . Furthermore, its targeted removal using RNAi (RNA interference) technology altered cancer-related properties of malignant cells, demonstrating that tumorigenic and metastatic properties of some cancer cell lines are dependent on TR1 expression [30] . Down-regulation of TR1 in a mouse cancer cell line driven by oncogenic k-ras has revealed that TR1-deficient cells lose self-sufficiency of growth, have a defective progression in their S-phase and exhibit a reduced expression of an enzyme involved in DNA replication, DNA polymerase-α [31] . These latter studies have shown that TR1 has major roles in several of the hallmarks of cancer described by Hanahan and Weinberg [32] , including metastasis and self-sufficiency in growth signals [30] .
Selenite can be used as a source of selenium for cell growth, but at higher levels this compound is toxic. Cancer cells are known to be more sensitive to selenite toxicity than normal cells, and the relative sensitivities of different cancers to this selenium anion also vary [33, 34] . Other reports have shown an inverse relationship between resistance to cytotoxic drugs and sensitivity to selenite in cancer cells [35, 36] . Selenite is thought to induce apoptosis through oxidative stress [37, 38] . It has been proposed that the mechanism of selenite cytotoxicity involves the generation of ROS (reactive oxygen species) through intracellular redox cycling with oxygen and cellular thiols [39] . However, the reason why cancer cells are more sensitive to selenite than normal cells is not clear. TR1 is known to have a broad substrate specificity, and GS-Se-SG (selenodiglutathione) and selenite were reported to be substrates for mammalian TR1 in biochemical studies [40, 41] , suggesting a role of TR1 in selenium metabolism or selenium cytotoxicity.
To elucidate the role of TR1 in selenite toxicity in cancer cells, we compared the relative selenite sensitivities of DT cells, a cancer cell line derived from NIH 3T3 cells [42] , with the parental cell line. DT and NIH 3T3 cells were made deficient in TR1 or Trx1 expression, and the effects of selenite and H 2 O 2 on the viability of these cells in relation to oxidative stress was examined. These studies demonstrated that a TR1-deficient cancer cell line, designated DT/siTR1, was more sensitive to selenite than the corresponding Trx1-deficient or control cells and that the level of GSH in TR1-deficient cells was significantly increased compared with other cells. The data suggest that TR1 deficiency caused an increased production of GSH, which in turn caused an enhanced cytotoxic response to TR1-deficient cells.
EXPERIMENTAL

Materials
Products were purchased as follows: H 2 O 2 , sodium selenite (Na 2 SeO 3 ), reduced GSH, GSSG, NAC (N-acetylcysteine), metaphosphoric acid, OPA (o-phthaldialdehyde), NEM (Nethylmaleimide), NADPH and guanidinium chloride were from Sigma; BCA (bicinchoninic acid) protein assay reagent and SuperSignal West were from Thermo Fisher Scientific; PVDF membrane, NuPage 4-12 % BisTris gels, the Trypan Blue exclusion test assay, DMEM (Dulbecco's modified Eagle's medium), antibiotic/antimycotic solution and fetal bovine serum were from Invitrogen Life Technologies; primary antibodies against Trx1, GSR (glutathione reductase) and GSS (glutathione synthetase) were from Abcam; a primary antibody against GST-α1 (glutathione transferase α1) was from Detroit R&D; and an anti-rabbit HRP (horseradish peroxidase)-conjugated secondary antibody was from Cell Signaling Technology. 75 Se was obtained from the Research Reactor Facility, University of Missouri, Columbia, MO, U.S.A.. NIH 3T3 cells and DT cells were obtained as described previously [42] .
Generation of TR1-and Trx1-deficient cells
Knockdown of TR1 in DT cells and preparation of the corresponding cell line encoding the pU6-m3 control vector that lacked the siRNA (small interfering RNA) sequence have been reported previously [31] . The control stably transfected pU6-m3 in DT and NIH 3T3 cells were produced as described previously [30] . Knockdown of TR1 and Trx1 in NIH 3T3 cells and of Trx1 in DT cells was carried out as described previously [30] , with the following exceptions: the Trx1 (TXN1) mRNA sequence (GenBank ® accession number NM_011660) was surveyed for targeting its removal using the same strategy used in generating TR1-knockdown DT cells [31] . The following nucleotide sequences were selected for targeting Trx1 mRNA: 5 -GCTCAGTCGTTTAGAACAT-3 , 5 -GCCACTG-CTTTAAGGCAAA-3 and 5 -CCAACTGCCATCTGATTAT-3 .
Culture of mammalian cells and cell viability
NIH 3T3 and DT cells were grown at 37
• C, 5 % CO 2 in DMEM supplemented with 10 % (v/v) fetal bovine serum and antibiotic/antimycotic solution which contained 10 000 units/ml penicillin, 10 000 μg/ml streptomycin and 25 μg/ml amphotericin B. Cells ( 
Quantification of GSH and GSSG
Concentrations of GSH and GSSG were measured as described previously using a fluorimetric method [43] . Briefly, cells were washed with PBS and homogenized with phosphate-EDTA buffer [0.1 M sodium phosphate and 5 mM EDTA (pH 8.0)]. Protein was quantitated using BCA protein assay reagent and precipitated with 5 % (w/v) metaphosphoric acid. Samples were mixed with 90 % (v/v) phosphate-EDTA buffer and 100 μg of OPA to measure the GSH concentration. To measure GSSG, cell extracts were treated with 4 mM NEM for 30 min at room temperature (25
• C) and mixed with 0.09 M NaOH and 100 μg of OPA. Reaction mixtures were incubated for 15 min at room temperature. Fluorescence was measured at excitation and emission wavelengths of 350 nm and 420 nm respectively. Pure GSH and GSSG were used to generate standard curves.
Western blot analysis, 75 Se labelling and TLC
Techniques used for Western blot analysis have been described previously [30, 31] . For 75 Se labelling, cells were seeded on to a six-well plate (3×10 5 cells/well) and labelled with 75 Se (40 μCi/well) for 24 h. Media samples were collected, the cells washed with PBS and then harvested. Media and lysate samples were separated by TLC using silica gel 60 F254 plates in chloroform/methanol/H 2 O (65:30:5, by vol.). GSH and 75 Se were used as controls and authentic labelled GS-Se-SG was prepared by incubating 75 Se and GSH in buffer [9] . After running, the plate was stained with ninhydrin and the 75 Se-glutathione conjugate in medium and the cell lysate was identified by autoradiography [30] . 75 Se-Labelled proteins were electrophoresed and detected as described [30, 31] .
RESULTS
Generation of TR1-and Trx1-deficient cells
We targeted the removal of TR1 or Trx1 in NIH 3T3 and DT cells by examining three sites in both TR1 (TXNRD1) and Trx1 mRNAs and selecting those most effective for protein removal [30, 31] . NIH 3T3 and DT cells were then stably transfected with the control construct pU6-m3, designated NIH 3T3/pU6-m3 and DT/pU6-m3 respectively, and with the most effective siTR1-and siTrx1-knockdown constructs, designated NIH 3T3/siTR1, DT/siTR1 and NIH 3T3/siTrx1 and DT/siTrx1 respectively. More than 90 % of TR1 and Trx1 appeared to be removed in stably transfected cell lines as determined by Western blot analysis ( Figure 1A ).
Effect of selenite and H 2 O 2 on TR1-deficient cells
Since DT cells were derived from NIH 3T3 cells [42] , the parental cell line provided a normal control for DT cells. We therefore compared these two cell lines in subsequent experiments. The relative sensitivities of both cell lines to selenite were examined (Supplementary Figure S1 http://www.BiochemJ.org/ bj/445/bj4450423add.htm). Significant differences were observed at 5 and 10 μM sodium selenite, wherein the parental cell line was little affected by 5 μM selenite, but the malignant cell line showed a pronounced inhibitory effect. At 10 μM, both cell lines were highly sensitive, but DT cells showed higher sensitivity. As 5 μM selenite appeared to be fairly non-toxic to NIH 3T3 cells, but an effective toxin to DT cells, this level of selenite was used in subsequent studies.
We next examined the sensitivities of NIH 3T3, DT and TR1-and Trx1-deficient cells to selenite, using two methods, the Trypan Blue exclusion method and the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide] assay. Toxicity of sodium selenite was increased in a dose-dependent manner in both cell lines, as was similarly shown using both methods ( Figure 1B and Supplementary Figure S2 at http://www.BiochemJ.org/ bj/445/bj4450423add.htm). Since significant differences between pU6-m3 control cells and TR1-and Trx1-deficient cells was observed at 5 μM ( Figure 1B ), this level of selenite was used in subsequent studies. Viability of TR1-and Trx1-deficient parental cells, NIH 3T3/siTR1 and NIH 3T3/siTrx1 respectively, upon treatment with selenite was similar and approximately half that of the control parental cell line ( Figure 1B and Supplementary Figure  S2 ). The sensitivity of DT/siTR1 cells to selenite was greater than DT/siTrx1 and DT/pU6-m3 control cells, whereas Trx1-deficient cells were only slightly more sensitive than control cells ( Figure 1B and Supplementary Figure S2 ). In addition, DT/siTR1 cells were proportionately more sensitive to selenite relative to their control cells than were NIH 3T3/siTR1 cells relative to their control cells (compare Figure 1B and Supplementary Figure S2 , top panel to bottom panel). The possible significance of these data is further considered below.
The finding that DT/siTR1 cells were far more sensitive to selenite than DT/siTrx1 cells was unexpected. This observation, the fact that TR1 is the primary reductant of Trx1 in normal mammalian cells [23] , and the observation that selenite-treated malignant cells have been proposed to suffer from oxidative stress [44, 45] , prompted us to determine whether the different sensitivities to selenite were due to cell death from oxidative stress or due to decreased growth rate. The three DT cell lines treated with buffer, selenite or H 2 O 2 were examined ( Figure 1C , top, middle and bottom panels respectively). DT/siTR1 and DT/siTrx1 cells were dying when treated with selenite and the reduced viability observed in the presence of this compound was therefore due to cell death. On the other hand, cell morphologies of these three cell lines were similar in response to H 2 O 2 , suggesting that the reduced cell numbers observed in the presence of this oxidant were due to decreased growth rates. Selenite-treated TR1-and Trx1-deficient cells were further examined to assess whether the decreases in cell viabilities were caused by apoptosis (Supplementary Figure S3 at http://www.BiochemJ.org/bj/445/bj4450423add.htm). The cell cycle was not affected by TR1 and Trx1 deficiency compared with control cells, and the sub-G 1 population was not altered significantly by selenite treatment. These data suggest that the reduced viability of cells by selenite was not caused by apoptosis.
Effect of selenite and H 2 O 2 on GSH metabolism
Since H 2 O 2 did not appear to affect TR1-and Trx1-deficient cells, we examined whether selenite might affect the expression of enzymes involved in the GSH system, especially in TR1-deficient cells. Thus mRNA levels of Gss, Gsr and Gsta1 were examined in DT/siTR1 and DT/siTrx1 cells treated with selenite or H 2 O 2 and compared with those in DT/pU6-m3 cells (Supplementary Figure S4 at http://www.BiochemJ.org/bj/ 445/bj4450423add.htm). These enzymes are involved in the biosynthesis of GSH (GSS), reduction of GSSG (GSR) or conjugation of GSH to toxic metabolites (GST-α1). Only the TR1-deficient cells exposed to selenite showed a dramatic increase in levels of all three mRNAs compared with treated and untreated control cells (Supplementary Figure S4) . To assess protein expression, Western blot analysis was performed on these enzymes showing that the enhanced levels of mRNAs for these enzymes also reflected an increase in their protein expression (Figure 2A ). Expression levels of GSS in DT/siTR1 cells were higher than in DT/pU6-m3 and DT/siTrx1 cells. Furthermore, TR1-deficient cells exposed to selenite showed an increase in levels of all three enzymes, especially in the expression of GST-α1 (compare Figure 2A , lane 5 to the other lanes). Trx1-deficient cells exposed to H 2 O 2 showed higher levels of GSR and GSS than cells exposed to selenite (compare Figure 2A , lane 9 with lanes 7 and 8, and Supplementary Figures S4A and S4B) . Interestingly, the levels of enzymes involved in GSH metabolism in DT/siTR1 cells exposed to H 2 O 2 were not as enriched as c The Authors Journal compilation c 2012 Biochemical Society in cells exposed to selenite. These results suggest that TR1-deficient cells require higher GSH levels to compensate for the loss of TR1 than control and even Trx1-deficient cells, especially when they are exposed to selenite.
To further elucidate a possible protective role for GSH under conditions of selenite toxicity caused by TR1 deficiency, intracellular GSH and GSSG and extracellular GSH levels in DT/pU6-m3, DT/siTR1 and DT/siTrx1 cells grown in the absence or presence of selenite or H 2 O 2 were examined by two different methods, the OPA histofluorescence method [43] and the tietze recycling method [46] (Figures 2B and 2C , and Supplementary Figure S5 at http://www.BiochemJ.org/bj/445/bj4450423add.htm respectively). Similar levels of intracellular GSH and GSSG were observed by both methods following exposure to selenite and H 2 O 2 with the exception that (and as anticipated) the amount of GSSG in selenite-treated cells measured by the tietze method manifested much higher levels of GSSG (Supplementary Figure  S5) when compared with the data obtained by the OPA method ( Figure 2B ). This was due to the fact that the tietze method uses GSR which is known to detect selenite-GSH conjugates such as GS-Se-SG in addition to GSSG, and GSR metabolizes both GSSG and GS-Se-SG [40] . Intracellular levels of GSH in TR1-deficient cells were approximately three times higher than in control cells. Selenite treatment totally depleted GSH in all three cell lines, but these cells had somewhat similar levels of GSH upon exposure to H 2 O 2 ( Figure 2B , left-hand panel). Intracellular levels of GSSG were low and similar in the three cell lines of control and selenite-exposed cells, but showed dramatic increases in DT/siTR1 and DT/siTrx1 cells exposed to H 2 O 2 compared with the corresponding control cells ( Figure 2B , right-hand panel); therefore the high amount of GSSG in malignant cells was likely to be due to a compromised Trx system. Extracellular or secreted levels of GSH in DT/siTR1 cells were more than three times higher under normal growth conditions, and selenite treatment triggered the increased secretion of GSH in all three cell lines, especially in TR1-deficient cells ( Figure 2C ).
Effect of GSH on selenite toxicity
To verify the role of extracellular GSH in protection against selenite toxicity caused by TR1 deficiency, we pretreated cells with GSH or NAC which is known to affect the production of this antioxidant. All cell lines exposed to only GSH or NAC did not show observable differences in viability, but pretreatment of cells with GSH or NAC prior to selenite treatment caused massive cell death in all cell lines (Figure 3) . The viability of all cell lines was less than 10 % when compared with GSH-or NAC-treated cells not treated with selenite.
To examine the effect of extracellular GSH on selenite cytotoxicity, cells were treated with GSH and labelled with 75 Se (Figure 4) . 75 Se conjugates were found in media and lysate samples by performing TLC (Figure 4) . The highest level of selenium-glutathione conjugate (most likely GS-Se-SG; see the Discussion section) was observed in TR1-deficient cells, and GSH treatment increased the selenium-glutathione conjugate levels, especially in the medium of control and Trx1-deficient cells ( Figure 4A ). DT/pU6-m3 control cells had an extremely low intracellular level of selenium-glutathione conjugate when compared with TR1-or Trx1-deficient cells, and GSH treatment significantly increased the intracellular level of selenium-glutathione conjugate in control cells but only slightly, if at all, in TR1-and Trx1-deficient cells ( Figure 4B ). As was previously reported, the addition of GSH resulted in increased levels of selenium-glutathione conjugate [40] , but the 
DISCUSSION
The Trx and GSH systems are regarded as major redox regulatory systems that maintain thiol redox homoeostasis in mammalian cells. These systems are of particular importance to cancer cells since cancer cells are known to suffer from oxidative stress and rely on these protective redox systems for survival [45] . In fact, enhanced Trx and GSH systems in tumour and cancer cells, their possible interrelationship and interdependence, and their roles as targets in cancer therapy have been recognized and examined in several studies [47, 48] . We have been interested in the role of TR1 in malignant cells, as this selenoenzyme is enriched in many cancer cells and tumours, and appears to have opposing roles in both preventing and promoting/sustaining cancer (see the Introduction). We first observed that DT cancer cells lacking TR1 were far more sensitive to selenite exposure than the corresponding Trx1-deficient or control cell lines, as well as the corresponding parental NIH 3T3 cells. This surprising finding suggested that the role of TR1 is not limited to the control of the redox state of Trx1. The sensitivity of TR1-deficient cells to selenite relative to control cells was also far greater in DT cells than in NIH 3T3 cells ( Figure 1B) . It should be noted that there is a discrepancy in the protective role of TR1 against selenite cytotoxicity. It was previously reported that selenium and GS-Se-SG were reduced by mammalian TR1 in the presence of NADPH [40, 41] , implicating TR1 in selenium metabolism and/or cytotoxicity. Cancer cells were found to express increased levels of TR1, but many cancer cell lines are more sensitive to selenite toxicity than normal cells [33, 34] , suggesting the involvement of another pathway that is affected in TR1-deficient cancer cells. TR1 is known to have a role in protecting cells from oxidative stress mainly via reduction of Trx1 [23, 49, 50] . In this regard, the differences in the consequences of TR1 and Trx1 deficiency upon selenite or H 2 O 2 exposure were especially interesting and unexpected. DT/pU6-m3, DT/siTR1 and DT/siTrx1 cells were treated with GSH and metabolically labelled with 75 Se for 24 h, and the media and cell extracts were examined. (A) Extracellular and (B) intracellular selenite-conjugated forms of GSH are shown which was observed by TLC. In (C), authentic GS-Se-SG generated in the reaction containing 75 Se and GSH is shown wherein 75 Se (left-hand panel) and ninhydrin-stained GSH (right-hand panel) were detected on the same thin-layer chromatogram.
To examine whether oxidative stress was involved in selenium cytotoxicity, we exposed control and TR1-or Trx1-deficient cell lines to sodium selenite or H 2 O 2 , wherein the latter agent was used as a positive control of oxidative stress. Different responses to those stresses were observed. The reduced viability of DT/TR1-and DT/Trx1-deficient cells following treatment with selenite was due to cell death, but it was not caused by apoptosis (Supplementary Figure S3) . In contrast, their diminished cell numbers following treatment with H 2 O 2 were due to decreased growth rates, even though H 2 O 2 is known to induce severe oxidative stress ( Figure 1C ). The levels of ROS in these three cell lines (i.e. DT/TR1-deficient, DT/Trx1-deficient and DT control cells) was assessed by DCFDA (2 ,7 -dichlorofluorescein diacetate) which is a procedure used for detecting general ROS. There were no significant differences in the cell lines up to 6 h following treatment with selenite, but ROS increased in DT/siTR1 cells at 24 h following treatment (Supplementary Figure  S7 at http://www.BiochemJ.org/bj/445/bj4450423add.htm). The mechanism of the increase in intracellular ROS in late stages of selenite-induced cell death in TR1-deficient cells requires further examination. H 2 O 2 appeared to increase GSH levels in control and Trx1-deficient cells. As expected, this treatment caused an accumulation of GSSG in TR1-and Trx1-deficient cells ( Figure 2B ), demonstrating that the GSH system decreased oxidative stress allowing cells to survive, and this phenomenon even occurred in cells having a functional Trx system. There was no significant change in GSSG levels by selenite treatment, again suggesting that these cells were not suffering from significant oxidative stress, or at least that selenite was simply acting through generation of H 2 O 2 .
We further investigated the role of GSH in protecting against selenite toxicity in DT/siTR1 cells by examining proteins involved in GSH production, the effect of selenite treatment on intracellular and extracellular GSH levels, and the effect of increased levels of extracellular GSH on selenite cytotoxicity. GSH levels in DT/siTR1 cells were approximately three times higher under normal growth conditions, but selenite treatment depleted intracellular GSH in all cells ( Figure 2B ). It was previously reported that deletion of TR1 in mouse hepatocytes induced the cytoprotective transcription factor Nrf2, and accordingly increased expression of phase II detoxification genes such as GSTs [25] , but the role of Trx1 in the induction of Nrf2 by TR1 deficiency was not examined in detail. We found that expression of GSS, GSR and GST-α1 was increased by selenite treatment (Figure 2A ) and that the extracellular levels of GSH, especially in DT/siTR1 cells, increased whereas intracellular levels of GSH were not restored by an increase in these enzymes ( Figure 2B , left-hand panel, and Figure 2C , right-hand panel). These observations showed that selenite treatment induced the production and secretion of GSH in DT/siTR1 cells, but not in DT/siTrx1 cells, suggesting that the regulation of GSH production and secretion by TR1 deficiency was not via Trx1. Pretreatment of GSH or NAC, which is known to induce the production of GSH, caused massive cell death in all cell lines (control cells, and TR1-and Trx1-deficient cells), whereas GSH and NAC itself did not affect cell viability. These latter observations suggested that extracellular levels of GSH had a direct relationship with seleniteinduced cell death and an increase in production and secretion of GSH in TR1-deficient cells that caused a higher sensitivity to selenite treatment. It has been proposed that selenium uptake and accumulation are crucial to specific selenite cytotoxicity in cancer cells, and the addition of extracellular GSH or thiol compounds along with selenite increased selenite cytotoxicity, suggesting that selenite uptake is controlled by the extracellular environment [39] . Recently, it was shown that GS-Se-SG was efficiently taken up by the vacuolar ABC (ATP-binding-cassette) transporter Ycf1p, and that overexpression of Ycf1p resulted in much higher selenite toxicity in yeast [51] . TR1-deficient cells produced and secreted much more GSH, manifested a high level of GS-Se-SG in the media and a much higher induction of GSH production and secretion following selenite treatment than control and Trx1-deficient cells. Thus the increased sensitivity of TR1-knockdown cells was apparently caused by increased GSH production and secretion.
Mammalian TR1 has been reported to directly reduce selenite to selenide and Se 0 species [41] . The latter selenium form may react with reduced glutathione to form GS-Se-SG that was proposed to be the major form of entry of selenocompounds into selenium metabolism [9, 52] . Furthermore, it was recently reported that other selenocompounds such as 2-butylselenazolidine-4(R)-carboxylic acid, 2-cyclohexylselenazolidine-4(R)-carboxylic acid and selenocystine were much more toxic to TR1-deficient cells [53] , and BSO, which is known to inhibit GSH synthesis, has been shown to inhibit tumour growth in TR1-knockout mice and to cause cell death in TR1-deficient cultured cells [53, 54] . The involvement of Trx1, however, in these studies was not investigated.
In the absence of TR1 (or GSH as a second line of defence), a partially reduced selenium species could interact with reduced thiols in proteins, modifying critical cysteine residues and disrupting protein function. Therefore further investigation of selenium metabolism in TR1-and Trx1-deficient cells following selenite exposure, and the interplay of GSH and TR1 in selenium metabolism and selenium cytotoxicity may provide fruitful avenues for cancer therapeutic strategies [48, 49] . DNA content of the cells was analysed by flow cytometry using a FACSCalbur 2 Sorter (Becton Dickinson) and the number of cells in each phase of the cell cycle was quantified by ModFit LT (Verity).
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Measurement of intracellular ROS levels
Intracellular ROS were measured using the fluorescent probe CM-DCFDA [5-(and 6)-chloromethyl DCFDA]. Cells (5×10 5 ) were seeded on 60 mm culture dishes, incubated overnight and then treated with sodium selenite. After incubating with 10 μM CM-DCFDA for 30 min at 37
• C, cells were harvested and intracellular ROS generation was analysed using a FACSCalibur 2 Sorter (Becton Dickinson). DT/pU6-m3, DT/siTR1 and DT/siTrx1cells were treated with 5 μM selenite for the indicated time periods between 10 min and 24 h, with 250 μM H 2 O 2 for 10 min, or were untreated. Cells were stained with 10 μM DCFDA for 30 min, harvested, suspended in PBS and ROS were measured by flow cytometry. No differences were observed in: (i) the control cells except those treated with H 2 O 2 ; (ii) TR1-deficient cells except a slight increase in ROS at 6 h and a much greater increase at 24 h; and (iii) Trx1-deficient cells except only a very slight increase in ROS at 6 h that increased at 24 h, but not as extensively at 24 h as in TR1-deficient cells (see the main text).
